Farrukh T. Awan, MBBS, discusses a phase II trial examining the clinical activity of entospletinib in patients with chronic lymphocytic leukemia who were previously treated with a B-cell receptor pathway signaling inhibitor.
Farrukh T. Awan, MBBS, associate professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses a phase II trial examining the clinical activity of entospletinib in patients with chronic lymphocytic leukemia (CLL) who were previously treated with a B-cell receptor pathway signaling inhibitor.
Awan says treatment for CLL is rapidly evolving at this time and many patients are being exposed to kinase inhibitor treatments. He adds that when a patient fails a TKI treatment, further treatment is not well-defined. Data from the phase II trial shows that entospletinib is a well-tolerated compand in patients with CLL.
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More